NMS offers the NHS over £500 million long-term savings, finds new study

NMS offers the NHS over £500 million long-term savings, finds new study

August 8, 2017

An economic evaluation looking at the cost-effectiveness of the New Medicine Service (NMS) has found that the service increased patient medicine adherence by 10% compared with normal practice, which translated into increased health gain at reduced overall cost.

The authors, from University College London and the Universities of Manchester and Nottingham, estimated that the NMS offers the NHS short-term savings of £75.4 million and long-term savings of £517.6 million.

They also suggest that consideration should be given to extending the NMS in other potentially beneficial therapeutic areas where there is significantly poor adherence.

Commenting on the findings of the study, Sue Sharpe, PSNC Chief Executive, said:

“The New Medicine Service (NMS) is provided by community pharmacists in pharmacies across the country. Pharmacists recognise that helping patients when they first receive a prescription for a new medicine can be pivotal to ensuring that they get the best possible outcomes. With the current pressures on the NHS it is vital to use community pharmacists to help support GPs and other parts of the health care system, using their expertise in medicines and the relationship they have with their patients.  Many people, particularly as they get older, depend on medicines to keep them well, and we are committed to developing community pharmacy’s support for them.”

Posted in:

More Latest News >

CPCS webinar now on-demand

Community pharmacy contractors can now access an online recording of our webinar about the new NHS Community Pharmacist Consultation Service...